- |||||||||| ST44 SESSION CANCELLED WBP: Myasthenia gravis (Scientific Theatre) - Jul 8, 2023 - Abstract #EAN2023EAN_2796;
In this talk, proposed by the Women's Brain Project, a neuroscientist and a patient living with MG will be discussing aspects related to the lived experience of MG with a particular focus on gender medicine. The role of hormones on symptoms and treatment response, as well as gendered stigma will be examined.
- |||||||||| Journal: COLQ-related congenital myasthenic syndrome: An integrative view. (Pubmed Central) - Jul 6, 2023
Apart from the weakness, extensive clinical heterogeneity was noted among patients with COLQ-related patients based on their genotypes-those with variants affecting the splice site exhibited more severe clinical features while those with missense variants displayed milder phenotypes, suggesting the role of differential splice variants in multiple functions within the muscle. Analyses and descriptions of these COLQ variants may be helpful in clinical trial readiness and potential development of novel therapies in the setting of established structure-function relationships.
- |||||||||| Biomarker, Journal, Epigenetic controller: Epigenome-wide DNA methylation analysis of myasthenia gravis. (Pubmed Central) - Jul 4, 2023
This is the first study to investigate genome-scale DNA methylation profiles of MG using 850K BeadChip. The identified molecular markers of methylation may aid in the prevention, diagnosis, treatment and prognosis of MG.
- |||||||||| azathioprine / Generic mfg.
A Case of Azathioprine-induced Hair Loss in a Patient with Myasthenia Gravis () - Jul 3, 2023 - Abstract #WCD2023WCD_5735; The hair grew back within one and a half months of stopping the azathioprine, as well as application of minoxidil 2% solution twice daily. KEY MESSAGE: This case highlights the complex interactions of medication, immunosuppression, autoimmunity, and the hair cycle equilibrium, as well as anagen effluvium as a rare possible side effect of azathioprine
- |||||||||| Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
Pemphigus vulgaris triggered by SARS-CoV-2 infection () - Jul 3, 2023 - Abstract #WCD2023WCD_5197; OBSERVATION: A 30-year-old gentleman was infected by SARS-CoV-2 6 months after primary tozinameran vaccination...KEY MESSAGE: Although uncommon, dermatologists should be aware of the potential for new-onset PV after SARS-CoV-2 infection. Immuno-profiling of patients may further our understanding of factors for susceptibility to autoimmunity after SARS-CoV-2 infection
- |||||||||| prednisone / Generic mfg.
Preclinical, Journal: Effects of Qishen Dihuang Granules on Intestinal Microbiota in Experimental Autoimmune Myasthenia Gravis Model Rats. (Pubmed Central) - Jul 3, 2023 Thirty-six female Lewis rats were assigned to Control, EAMG, QSDH-low-dose, QSDH-medium-dose, QSDH-high-dose, and Prednisone groups using the random number table method (6 rats/group)...The most significant inter-group genus-level community marker differences involved Prevotella, Ruminococcus, Coprococcus, and Turicibacter. QSDH granules may regulate EAMG rat intestinal flora by decreasing relative abundances of Turicibacter and Clostridium and increasing relative abundances of Bifidobacterium, Lachnospiraceae, and Prevotella.
- |||||||||| Review, Journal: Liver Metastasis of Thymoma: Case Report and Review of the Literature. (Pubmed Central) - Jul 3, 2023
We herein report a well-documented case of type B1 thymoma with relatively limited stage (IIb) with an isolated, single liver metastasis occurring seven years after primary resection in a patient with concomitant myasthenia gravis. The following report includes a review of the literature, a discussion of thymoma classification and its relevance to prognosis, and an overview of other extra-thoracic metastatic thymoma cases.
- |||||||||| Journal, CAR T-Cell Therapy: Are CAR T cells the answer to myasthenia gravis therapy? (Pubmed Central) - Jun 28, 2023
rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases. No abstract available
- |||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Review, Journal: Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker. (Pubmed Central) - Jun 28, 2023 Efgartigimod, an FcRn inhibitor, has shown promise in reducing the levels of autoantibodies and alleviating the autoimmune severity of myasthenia gravis, primary immune thrombocytopenia, and pemphigus vulgaris/foliaceus. This article aims to provide an overview of the importance of FcRn in antigen-presenting cells and its potential as a therapeutic target in autoimmune diseases, using efgartigimod as an example.
- |||||||||| Trial completion date, Trial primary completion date: Acupuncture in Myasthenia Gravis (AcuMG) (clinicaltrials.gov) - Jun 27, 2023
P=N/A, N=20, Recruiting, This article aims to provide an overview of the importance of FcRn in antigen-presenting cells and its potential as a therapeutic target in autoimmune diseases, using efgartigimod as an example. Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- |||||||||| Novel therapies for myasthenia gravis () - Jun 26, 2023 - Abstract #ANA2023ANA_179;
Sponsored by NMDPHARMA The presentation will focus on newer therapies for MG including complement inhibitors and FcR inhibitors with the rationale for use and clinical trial evidence of efficacy.
- |||||||||| Neuromuscular Disease () - Jun 26, 2023 - Abstract #ANA2023ANA_177;
Diagnose and provide CMT1A patients with the current knowledge regarding the recent development of CMT1A therapies. Select the appropriate therapeutic agents for individuals with myasthenia gravis.
- |||||||||| Biomarker, Journal: Plasma C18:0-ceramide is a novel potential biomarker for disease severity in myasthenia gravis. (Pubmed Central) - Jun 26, 2023
Importantly, only C18:0-Cer was shown to be positively associated with the concentration of serum IL and circulating memory B cells, and the decrease in plasma C18:0-Cer paralleled the clinical improvement of patients with MG. All together, our data suggest that ceramides may play an important role in the immunopathological mechanism of MG, and C18:0-Cer has the potential to be a novel biomarker for disease severity in MG.
- |||||||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Myasthenia-like paraneoplastic syndrome with multiple cranial nerve tumor infiltration: A case report and literature review. (Pubmed Central) - Jun 23, 2023 Cerebrospinal fluid testing should be carried out along with electrophysiological, serological, and pharmacological procedures pertinent to the diagnosis of MG to thoroughly examine if people simultaneously experience MG-like PNPS and tumor growth. Starting immunotherapy and anticancer medication at the same time that tumor development and MG-like syndrome are discovered is crucial.
- |||||||||| amoxicillin / Generic mfg.
Journal: Relationship between medical history and multiple sclerosis: A-case-control study. (Pubmed Central) - Jun 23, 2023 The adjusted risks of MS were 4.40; 95% CI: 1.73 to 11.1 for measles and 4.75; 95% CI: 2.05 to 11 for amoxicillin consumption...On the other hand, the calculated adjusted odds of MS occurrence were 0.14; 95% CI: 0.03 to 0.69 for seizure and 0.17; 95% CI: 0.02 to 1.49 for epilepsy. This study suggested that individuals with autoimmune diseases should be monitored more closely, as they may be at an increased risk of developing other autoimmune conditions, particularly MS.
|